Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas

REFERENCES

• Abbondanzo S. L., Wenig B. M. Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995; 75: 1281–1291
   PubMed Web of Science ®Google Scholar
• Alileche A., Goldman C. K., Waldmann T. A. Differential effects of IL-2 and IL-15 on expression of IL-2 receptor-α. Biochem. Biophys. Res. Commun. 2001; 285: 1302–1308
   PubMedGoogle Scholar
• Anderson D. M., Kumaki S., Ahdieh M., Bertles J., Tometsko M., Loomis A., Giri J., Copeland N. G., Gilbert D. J., Jenkins N. A., Valentine V., Shapiro D. N., Morris S. W., Park L. S., Cosman D. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15Rα and IL2Rα genes. J. Biol. Chem. 1995; 270: 29862–29869
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Horwitz S. M., Engert A., Khan K. D., Lin T., Strair R., Keler T., Graziano R., Blanset D., Yellin M., Fischkoff S., Assad A., Borchmann P. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 2007; 25: 2764–2769
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Weisenburger D. D. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Bamford R. N., Battiata A. P., Burton J. D., Sharma H., Waldmann T. A. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. USA 1996; 93: 2897–2902
   PubMed Web of Science ®Google Scholar
• Barberio E., Thomas L., Skowron F., Balme B., Dalle S. Transformed mycosis fungoides: Clinicopathological features and outcome. Br. J. Dermatol. 2007; 157: 284–289
   PubMed Web of Science ®Google Scholar
• Barth S., Huhn M., Matthey B., Tawadros S., Schnell R., Schinköthe T., Diehl V., Engert A. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909–3914
   PubMed Web of Science ®Google Scholar
• Bartlett N. L., Younes A., Carabasi M. H., Forero A., Rosenblatt J. D., Leonard J. P., Bernstein S. H., Bociek R. G., Lorenz J. M., Hart B. W., Barton J. A Phase 1 multi-dose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2007, [Epub ahead of print]
   PubMedGoogle Scholar
• Borchmann P., Treml J. F., Hansen H., Gottstein C., Schnell R., Staak O., Zhang H. F., Davis T., Keler T., Diehl V., Graziano R. F., Engert A. The human anti-CD30 antibody 5F11 shows in vitro in vivo activity against malignant lymphoma. Blood 2003; 102: 3737–3742
   PubMed Web of Science ®Google Scholar
• Borrione P., Montacchini L., Beggiato E., Pileri A., Bianchi A., Massaia M. Clinical and immunological studies in advanced cancer patients sequentially treated with anti-CD3 monoclonal antibody (OKT3) and interleukin-2. Leuk. Lymphoma 1996; 21: 325–330
   PubMed Web of Science ®Google Scholar
• Bowen M. A., Olsen K. J., Cheng L., Avila D., Podack E. R. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol. 1993; 151: 5896–5906
   PubMed Web of Science ®Google Scholar
• Branco L., Barren P., Mao S. Y., Pfarr D., Kaplan R., Postema C., Langermann S., Koenig S., Johnson S. Selective deletion of antigen-specific, activated T-cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588–1596
   PubMedGoogle Scholar
• Cario G., Izraeli S., Teichert A., Rhein P., Skokowa J., Möricke A., Zimmermann M., Schrauder A., Karawajew L., Ludwig W. D., Welte K., Schünemann H. J., Schlegelberger B., Schrappe M., Stanulla M. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J. Clin. Oncol. 2007; 25: 4813–4820
   PubMed Web of Science ®Google Scholar
• Chamian F., Lowes M. A., Lin S. L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K. M., Krueger J. G. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 2005; 102: 2075–2080
   PubMed Web of Science ®Google Scholar
• Chatenoud L. CD3-specific antibody-induced active tolerance: From bench to bedside. Nat. Rev. Immunol. 2003; 3: 123–132
   PubMed Web of Science ®Google Scholar
• Chittal S. M., Caverivière P., Schwarting R., Gerdes J., Al Saati T., Rigal-Huguet F., Stein H., Delsol G. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am. J. Surg. Pathol. 1988; 12: 9–21
   PubMed Web of Science ®Google Scholar
• Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl. J. Med. 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Criscione V. D., Weinstock M. A. Incidence of cutanenous T-cell lymphoma in the United States, 1973–2002. Arch. Dermatol. 2007; 143: 854–859
   PubMed Web of Science ®Google Scholar
• Dearden C. E., Matutes E., Cazin B., Tjønnfjord G. E., Parreira A., Nomdedeu B., Leoni P., Clark F. J., Radia D., Rassam S. M., Roques T., Ketterer N., Brito-Babapulle V., Dyer M. J., Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721–1726
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Shawler D. L., Dillman J. B., Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 1984; 2: 881–891
   PubMed Web of Science ®Google Scholar
• Döbbeling U., Dummer R., Laine E., Potoczna N., Qin J. Z., Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92: 252–258
   PubMed Web of Science ®Google Scholar
• Dyer M. J. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin. Oncol. 1999; 26(5S14)52–57
   PubMedGoogle Scholar
• Falini B., Bolognesi A., Flenghi L., Tazzari P. L., Broe M. K., Stein H., Dürkop H., Aversa F., Corneli P., Pizzolo G., Barbabietola G., Sabattini E., Pileri S., Martelli M. F., Stirpe F. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–1196
   PubMed Web of Science ®Google Scholar
• Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Feldman A. L., Pittaluga S., Jaffe E. S. Classification and histopathology of the lymphomas. The Lymphomas, 2nd Edition, G. P. Canellos, T. A. Lister, B. Young. Saunders-Elsevier, Philadelphia 2006; 2–38
   Google Scholar
• Foss F. M., Saleh M. N., Krueger J. G., Nichols J. C., Murphy J. R. Diphtheria toxin fusion proteins. Curr. Top. Microbiol. Immunol. 1998; 234: 63–81
   PubMed Web of Science ®Google Scholar
• Foss F., Sjak-Shie N., Goy A., Jacobsen E., Advani R., Smith M., Komrokji R., Pendergrass K., Bolejack V., Watts K., Acosta M. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial. Blood 2007; 110: 3449, (ASH Annual Meeting Abstracts)
   Google Scholar
• Gallamini A., Zaja F., Patti C., Billio A., Specchia M. R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., Tarella C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–2323
   PubMed Web of Science ®Google Scholar
• Garcia K. C., Adams E. J. How the T-cell receptor sees antigen—A structural view. Cell 2005; 122: 333–336
   PubMedGoogle Scholar
• Giri J. G., Anderson D. M., Kumaki S., Park L. S., Grabstein K. H., Cosman D. IL-15, a novel T-cell growth factor that shares activities and receptor components with IL-2. J. Leukocyte Biol. 1995; 57: 763–766
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Gaulard P., Lepage E., Coiffier B., Brière J., Haioun C., Cazals-Hatem D., Bosly A., Xerri L., Tilly H., Berger F., Bouhabdallah R., Diebold J. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Gramatzki M., Burger R., Strobel G., Trautmann U., Bartram C. R., Helm G., Horneff G., Alsalameh S., Jonker M., Gebhart E., Kalden J. R. Therapy with OKT3 monoclonal antibody in refractory T-cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia 1995; 9: 382–390
   PubMedGoogle Scholar
• Groves F. D., Linet M. S., Travis L. B., Devesa S. S. Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J. Natl. Cancer Inst. 2000; 92: 1240–1251
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y., Raber J., Chan C. C., Kriete M. S., Benichou J., Pilson R. S., Kerwin J. A., Waldmann T. A., Hakimi J., Roberge F. G. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the β -chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J. Immunol. 1997; 158: 452–458
   PubMed Web of Science ®Google Scholar
• Hakimi J., Ha V. C., Lin P., Campbell E., Gately M. K., Tsudo M., Payne P. W., Waldmann T. A., Grant A. J., Tsien W. H., Schneider W. P. Humanized Mik β 1, a humanized antibody to the IL-2 receptor β -chain that acts synergistically with humanized anti-TAC. J. Immunol. 1993; 151: 1075–1085
   PubMed Web of Science ®Google Scholar
• Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A. J., Waldmann H. Removal of T-cells from bone marrow for transplantation: A monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882
   PubMed Web of Science ®Google Scholar
• Hamblett K. J., Barton J., Cerveny C. G., Andreyka J. B., Kissler K. M., Okeley N. M., Stone I., Sutherland M. K., Sun M. M., Senter P. D., Wahl A. F., Ihle N. C. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent anti-tumor activity for the treatment of CD30+ malignancies. Blood 2005; 106: 610, (ASH Annual Meeting Abstracts)
   Google Scholar
• Hecht T. T., Longo D. L., Cossman J., Bolen J. B., Hsu S. M., Israel M., Fisher R. I. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J. Immunol. 1985; 134: 4231–4236
   PubMed Web of Science ®Google Scholar
• Holmes G. K. Coeliac disease and malignancy. Dig. Liver Dis. 2002; 34: 229–237
   PubMedGoogle Scholar
• Hsu S. M., Yang K., Jaffe E. S. Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Am. J. Pathol. 1985; 118: 209–217
   PubMed Web of Science ®Google Scholar
• Hu X. F., Xing P. X. MDX-060. Medarex. Curr. Opin. Invest. Drugs 2005; 6: 1266–1271
   PubMedGoogle Scholar
• Hurst R. E. Bexarotene ligand pharmaceuticals. Curr. Opin. Invest. Drugs 2000; 1: 514–523
   PubMedGoogle Scholar
• Jaffe E. S., Harris N. L., Stein H., Vardiman J. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, LyonFrance 2001
   Google Scholar
• Janik J. E., Dunleavy K., Pittaluga S., Jaffe E. S., Grant N., Shovlin M., Stetler-Stevenson M., Wilson W. H. A pilot trial of Campath-1H and dose-Adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood 2005; 106: 3348, (ASH Annual Meeting Abstracts)
   PubMedGoogle Scholar
• Jermal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66
   PubMedGoogle Scholar
• Johnson J. M., Harrod R., Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int. J. Exp. Pathol. 2001; 82: 135–147
   PubMed Web of Science ®Google Scholar
• Junghans R. P., Stone A. L., Lewis M. S. Biophysical characterization of a recombinant soluble interleukin-2 receptor (Tac). J. Biol. Chem. 1996; 271: 10453–10460
   PubMedGoogle Scholar
• Kanegane H., Tosato G. Activation of naive and memory T-cells by interleukin-15. Blood 1996; 88: 230–235
   PubMed Web of Science ®Google Scholar
• Keating M. J., Flinn I., Jain V., Binet J. L., Hillmen P., Byrd J., Albitar M., Brettman L., Santabarbara P., Wacker B., Rai K. R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Kim J. G., Sohn S. K., Chae Y. S., Cho Y. Y., Yang D. H., Lee J. J., Kim H. J., Shin H. J., Chung J. S., Cho G. J., Lee W. S., Joo Y. D., Sohn C. H., Oh S. J. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: A Phase II study. Cancer Chemother. Pharmacol. 2007; 60: 129–134
   PubMed Web of Science ®Google Scholar
• Kim Y. H., Duvic M., Obitz E., Gniadecki R., Iversen L., Osterborg A., Whittaker S., Illidge T. M., Schwarz T., Kaufmann R., Cooper K., Knudsen K. M., Lisby S., Baadsgaard O., Knox S. J. Clinical efficacy of zanolimumab (HuMax-CD4): Two Phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655–4662
   PubMed Web of Science ®Google Scholar
• Kirk A. D. Induction immunosuppression. Transplantation 2006; 82: 593–602
   PubMed Web of Science ®Google Scholar
• Knop S., Hebart H., Gratwohl A., Kliem C., Faul C., Holler E., Apperley J., Kolb H. J., Schaefer A., Niederwieser D., Einsele H. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: A randomized multi-center trial by the EBMT Chronic Leukemia Working Party. Leukemia 2007; 21: 1830–1833
   PubMed Web of Science ®Google Scholar
• Knox S., Hoppe R. T., Maloney D., Gibbs I., Fowler S., Marquez C., Cornbleet P. J., Levy R. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893–899
   PubMedGoogle Scholar
• Knox S. J., Levy R., Hodgkinson S., Bell R., Brown S., Wood G. S., Hoppe R., Abel E. A., Steinman L., Berger R. G., Gaiser C., Young G., Bindl J., Hanham A., Reichert T. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77: 20–30
   PubMed Web of Science ®Google Scholar
• Kobayashi H., Dubois S., Sato N., Sabzevari H., Sakai Y., Waldmann T. A., Tagaya Y. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005; 105: 721–727
   PubMed Web of Science ®Google Scholar
• Koenecke C., Shaffer J., Alexander S. I., Preffer F., Dombkowski D., Saidman S. L., Dey B., McAfee S., Spitzer T. R., Sykes M. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp. Hematol. 2003; 31: 911–923
   PubMedGoogle Scholar
• Kreitman R. J., Wilson W. H., White J. D., Stetler-Stevenson M., Jaffe E. S., Giardina S., Waldmann T. A., Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 2000; 18: 1622–1636
   PubMed Web of Science ®Google Scholar
• Kung P., Goldstein G., Reinherz E. L., Schlossman S. F. Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 1979; 206: 347–349
   PubMed Web of Science ®Google Scholar
• Leahy D. J. A structural view of CD4 and CD8. FASEB J. 1995; 9: 17–25
   PubMed Web of Science ®Google Scholar
• Ledbetter J. A., Rouse R. V., Micklem H. S., Herzenberg L. A. T-Cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J. Exp. Med. 1980; 152: 280–295
   PubMed Web of Science ®Google Scholar
• Lennert K., Kikuchi M., Sato E., Suchi T., Stansfeld A. G., Feller A. C., Hansmann M. L., Müller-Hermelink H. K., Gödde-Salz E. HTLV-positive and -negative T-cell lymphomas. Morphological and immunohistochemical differences between European and HTLV-positive Japanese T-cell lymphomas. Int. J. Cancer 1985; 35: 65–72
   PubMed Web of Science ®Google Scholar
• Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005; 23: 1117–1125
   PubMed Web of Science ®Google Scholar
• López-Guillermo A., Cid J., Salar A., López A., Montalbán C., Castrillo J. M., González M., Ribera J. M., Brunet S., García-Conde J., Fernández de Sevilla A., Bosch F., Montserrat E. Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann. Oncol. 1998; 9: 849–855
   PubMed Web of Science ®Google Scholar
• Lowenstein H., Shah A., Chant A., Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transpl. Int. 2006; 19: 927–936
   PubMed Web of Science ®Google Scholar
• Lozano F., Simarro M., Calvo J., Vilà J. M., Padilla O., Bowen M. A., Campbell K. S. CD5 signal transduction: Positive or negative modulation of antigen receptor signaling. Crit. Rev. Immunol. 2000; 20: 347–358
   PubMedGoogle Scholar
• Lundin J., Hagberg H., Repp R., Cavallin-Ståhl E., Fredén S., Juliusson G., Rosenblad E., Tjønnfjord G., Wiklund T., Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267–4272
   PubMed Web of Science ®Google Scholar
• Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Ann. Rev. Immunol. 2006; 24: 657–679
   PubMed Web of Science ®Google Scholar
• Majeau G. R., Meier W., Jimmo B., Kioussis D., Hochman P. S. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T-cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 1994; 152: 2753–2767
   PubMed Web of Science ®Google Scholar
• Mann B. S., Johnson J. R., Cohen M. H., Justice R., Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247–1252
   PubMed Web of Science ®Google Scholar
• Marti R. M., Pujol R. M., Servitje O., Palou J., Romagosa V., Bordes R., González-Castro J., Miralles J., Gallardo F., Curcó N., Gómez X., Domingo A., Estrach T. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003; 44: 59–69
   PubMed Web of Science ®Google Scholar
• Mascelli M. A., Zhou H., Sweet R., Getsy J., Davis H. M., Graham M., Abernethy D. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development. J. Clin. Pharmacol. 2007; 47: 553–565
   PubMed Web of Science ®Google Scholar
• Matutes E. Adult T-cell leukaemia/lymphoma. J. Clin. Pathol. 2007; 60: 1373–1377
   PubMed Web of Science ®Google Scholar
• McInnes I. B., Gracie J. A. Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 2004; 4: 392–397
   PubMed Web of Science ®Google Scholar
• Medeiros L. J., Elenitoba-Johnson K. S. Anaplastic large cell lymphoma. Am. J. Clin. Pathol. 2007; 127: 707–722
   PubMed Web of Science ®Google Scholar
• Miller R. A., Oseroff A. R., Stratte P. T., Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983; 62: 988–995
   PubMed Web of Science ®Google Scholar
• Moingeon P. E., Lucich J. L., Stebbins C. C., Recny M. A., Wallner B. P., Koyasu S., Reinherz E. L. Complementary roles for CD2 and LFA-1 adhesion pathways during T-cell activation. Eur. J. Immunol. 1991; 21: 605–610
   PubMedGoogle Scholar
• Moingeon P., Chang H. C., Sayre P. H., Clayton L. K., Alcover A., Gardner P., Reinherz E. L. The structural biology of CD2. Immunol. Rev. 1989; 111: 111–144
   PubMed Web of Science ®Google Scholar
• Morris J. C., Janik J. E., Turner M., Lee C., Quinn C., Pittaluga S., Stetler-Stevenson M., Fleisher T. A., Albert P., Waldmann T. A. A Phase I trial of humanized anti-Tac (daclizumab) for the treatment of human T-cell lymphotrophic virus Type-1-associated leukemia/lymphoma. Proc. Am. Soc. Clin. Oncol 2003; 22: 695
   Google Scholar
• Morris J. C., Janik J. E., White J. D., Fleisher T. A., Brown M., Tsudo M., Goldman C. K., Bryant B., Petrus M., Top L., Lee C. C., Gao W., Waldmann T. A. Preclinical and Phase I clinical trial of blockade of IL-15 using Mik-β -1 monoclonal antibody in T-cell large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. USA 2006; 103: 401–406
   PubMed Web of Science ®Google Scholar
• Nashan B., Light S., Hardie I. R., Lin A., Johnson J. R. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110–115
   PubMed Web of Science ®Google Scholar
• Nelson B. H., Willerford D. M. Biology of the interleukin-2 receptor. Adv. Immunol. 1998; 70: 1–81
   PubMed Web of Science ®Google Scholar
• Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Norton A. J., Isaacson P. G. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. Am. J. Pathol. 1987; 128: 225–240
   PubMed Web of Science ®Google Scholar
• Nosari A., Montillo M., Morra E. Infectious toxicity using alemtuzumab. Haematologica 2004; 89: 1414–1419
   Google Scholar
• O'Mahony D., Morris J. C., Carrasquillo J. A., Le N., Paik C., Whatley M., Pittaluga S., Fleischer T. A., Lee C., Gao W., O'Hagan D., Waldmann T. A., Janik J. E. A Phase I/II study of yttrium-90-labeled humanized monoclonal anti-Tac antibody and calcium-DTPA in patients with CD25-expressing lymphoid malignancies. J. Nucl. Med. 2006; 47(S1)279
   Google Scholar
• O'Mahony D., Morris J. C., Moses L., O'Hagan D., Matthews H., Stetler-Stevenson M., Urquhart N., Kaucic K., Hammershaimb L., Warfe G., Waldmann T. A., Janik J. E. A Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. AIDS Res. Hum. Retrovir 2007a; 23: 598
   Google Scholar
• O'Mahony D., Morris J. C., Stetler-Stevenson M., Matthews H., Pittaluga S., Albert P., Kaucic K., Hammershaimb L., Waldmann T. A., Janik J. E. EBV-related lymphoproliferative disease complicating therapy with siplizumab, a novel anti-CD2 mediated T- and NK cell depleting agent, in patients with T-cell malignancies. Blood 2007b; 110: 1043, (ASH Annual Meeting Abstracts)
   PubMedGoogle Scholar
• Ohno T., Yamaguchi M., Oka K., Miwa H., Kita K., Shirakawa S. Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia 1995; 9: 44–52
   PubMed Web of Science ®Google Scholar
• Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., Oseroff A., Pinter-Brown L., Bowen G., Kuzel T., Fivenson D., Foss F., Glode M., Molina A., Knobler E., Stewart S., Cooper K., Stevens S., Craig F., Reuben J., Bacha P., Nichols J. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 2001; 19: 376–388
   PubMed Web of Science ®Google Scholar
• Olsen N. J., Brooks R. H., Cush J. J., Lipsky P. E., St. Clair E. W., Matteson E. L., Gold K. N., Cannon G. W., Jackson C. G., McCune W. J., Fox D. A., Nelson B., Lorenz T., Strand V. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 1996; 39: 1102–1108
   PubMedGoogle Scholar
• O'Malley D. P. T-Cell large granular leukemia and related proliferations. Am. J. Clin. Pathol. 2007; 127: 850–859
   PubMed Web of Science ®Google Scholar
• Phillips K. E., Herring B., Wilson L. A., Rickford M. S., Zhang M., Goldman C. K., Tso J. Y., Waldmann T. A. IL-2Rα -directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction. Cancer Res. 2000; 60: 6977–6984
   PubMed Web of Science ®Google Scholar
• Poiesz B. J., Papsidero L. D., Ehrlich G., Sherman M., Dube S., Poiesz M., Dillon K., Ruscetti F. W., Slamon D., Fang C., Williams A., Duggan D., Glaser J., Gottlieb A., Goldberg J., Ratner L., Phillips P., Han T., Friedman-Kien A., Siegal F., Rai K., Sawitsky A., Sheremata L. W., Dosik H., Cunningham C., Montagna R. Prevalence of HTLV-I-associated T-cell lymphoma. Am. J. Hematol. 2001; 66: 32–38
   PubMed Web of Science ®Google Scholar
• Poiesz B. J., Ruscetti F. W., Gazdar A. F., Bunn P. A., Minna J. D., Gallo R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 1980; 77: 7415–7419
   PubMed Web of Science ®Google Scholar
• Przepiorka D., LeMaistre C. F., Huh Y. O., Luna M., Saria E. A., Brown C. T., Champlin R. E. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Ther. Immunol. 1994; 1: 77–82
   PubMedGoogle Scholar
• Przepiorka D., Phillips G. L., Ratanatharathorn V., Cottler-Fox M., Sehn L. H., Antin J. H., LeBherz D., Awwad M., Hope J., McClain J. B. A Phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 4066–4071
   PubMed Web of Science ®Google Scholar
• Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1989; 86: 10029–10033
   PubMed Web of Science ®Google Scholar
• Raman C. CD5, an important regulator of lymphocyte selection and immune tolerance. Immunol. Res. 2002; 26: 255–263
   PubMedGoogle Scholar
• Ravandi F., O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006; 24: 718–725
   PubMed Web of Science ®Google Scholar
• Ravel S., Colombatti M., Casellas P. Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T-cells. Blood 1992; 79: 1511–1517
   PubMedGoogle Scholar
• Robb R. J., Munck A., Smith K. A. T-Cell growth factor receptors. J. Exp. Med. 1982; 154: 1455–1474
   Google Scholar
• Rubin L. A., Kurman C. C., Biddison W. E., Goldman N. D., Nelson D. L. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma 1985; 4: 91–102
   PubMedGoogle Scholar
• Sanchez-Madrid F., Davignon D., Martz E., Springer T. A. Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: Functional screening and topographic relationship. Cell. Immunol. 1982; 73: 1–11
   PubMed Web of Science ®Google Scholar
• Sasada T., Reinherz E. L. A critical role for CD2 in both thymic selection events and mature T cell function. J. Immunol. 2001; 166: 2394–2403
   PubMedGoogle Scholar
• Schneider C., Hübinger G. Pleiotropic signal transduction mediated by human CD30: A member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002; 43: 1355–1366
   PubMed Web of Science ®Google Scholar
• Schnell R., Staak O., Borchmann P., Schwartz C., Matthey B., Hansen H., Schindler J., Ghetie V., Vitetta E. S., Diehl V., Engert A. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin. Cancer Res. 2002; 8: 1779–1786
   PubMed Web of Science ®Google Scholar
• Sehn L. H., Donaldson J., Chanabhai M., Fitzgerald C., Gill K., Klasa R., MacPherson N., O'Reilly S., Spinelli J. J., Sutherland J., Wilson K. S., Gascoyne R. D., Connors J. M. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 2005; 23: 502–5033
   PubMedGoogle Scholar
• Shaffer J., Villard J., Means T. K., Alexander S., Dombkowski D., Dey B. R., McAfee S., Ballen K. K., Saidman S., Preffer F. I., Sachs D. H., Spitzer T. R., Sykes M. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp. Hematol. 2007; 35: 1140–1152
   PubMedGoogle Scholar
• Shanmugham L. N., Petrarca C., Frydas S., Donelan J., Castellani M. L., Boucher W., Madhappan B., Tete S., Falasca K., Conti P., Vecchiet J. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. J. Exp. Clin. Cancer Res. 2006; 25: 529–536
   PubMed Web of Science ®Google Scholar
• Sharma K., Janik J. E., O'Mahoney D., Lee C. C., O'Hagan D., Gao W., Wharfe G., Cranston B., Waldmann T. A., Morris J. C. A Phase II study of the efficacy and toxicity of alemtuzumab (CAMPATH-1H) for the therapy of human T-cell lymphotrophic virus-1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL). Proc. Am. Soc. Clin. Oncol 2006; 24: 2535
   Google Scholar
• Skov L., Kragballe K., Zachariae C., Obitz E. R., Holm E. A., Jemec G. B., Sølvsten H., Ibsen H. H., Knudsen L., Jensen P., Petersen J. H., Menné T., Baadsgaard O. HuMax-CD4: A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 2003; 139: 1433–1439
   PubMed Web of Science ®Google Scholar
• Stein H., Foss H. D., Dürkop H., Marafioti T., Delsol G., Pulford K., Pileri S., Falini B. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681–3695
   PubMed Web of Science ®Google Scholar
• Strand V., Lipsky P. E., Cannon G. W., Calabrese L. H., Wiesenhutter C., Cohen S. B., Olsen N. J., Lee M. L., Lorenz T. J., Nelson B. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two Phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 1993; 36: 620–630
   PubMedGoogle Scholar
• Teh S. J., Killeen N., Tarakhovsky A., Littman D. R., Teh H. S. CD2 regulates the positive selection and function of antigen-specific CD4− CD8+ T-cells. Blood 1997; 89: 1308–1318
   PubMedGoogle Scholar
• Tendler C. L., Greenberg S. J., Blattner W. A., Manns A., Murphy E., Fleisher T., Hanchard B., Morgan O., Burton J. D., Nelson D. L., Waldmann T. A. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy. Proc. Natl. Acad. Sci. USA 1990; 87: 5218–5222
   PubMed Web of Science ®Google Scholar
• Tesch H., Günther A., Abts H., Jücker M., Klein S., Krueger G. R., Diehl V. Expression of interleukin-2Rα and interleukin-2Rβ in Hodgkin's disease. Am. J. Pathol. 1993; 142: 1714–1720
   PubMed Web of Science ®Google Scholar
• Tinubu S. A., Hakimi J., Kondas J. A., Bailon P., Familletti P. C., Spence C., Crittenden M. D., Parenteau G. L., Dirbas F. M., Tsudo M., Bather J. D., Kasten-Sportes C., Martinucci J. L., Carolyn K, Goldman C. K., Clark R. E., Waldmann T. A. Humanized antibody directed to the IL-2 receptor β -chain prolongs primate cardiac allograft survival. J. Immunol. 1994; 153: 4330–4338
   PubMed Web of Science ®Google Scholar
• Tkaczuk J., Yu C. L., Baksh S., Milford E. L., Carpenter C. B., Burakoff S. J., McKay D. B. Effect of anti-IL-2Rα antibody on IL-2-induced Jak/STAT signaling. Am. J. Transplant. 2002; 2: 31–40
   PubMedGoogle Scholar
• Treumann A., Lifely M. R., Schneider P., Ferguson M. A. Primary structure of CD52. J. Biol. Chem. 1995; 270: 6088–6099
   PubMed Web of Science ®Google Scholar
• Tsudo M., Kitamura F., Miyasaka M. Characterization of the IL-2 receptor β chain using three distinct monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1989; 86: 1982–1986
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 1981a; 126: 1393–1397
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Nelson D. L., Fleisher T. A., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. II. Expression of Tac antigen on activated cytotoxic killer T-cells, suppressor cells, and on one of two types of helper T-cells. J. Immunol. 1981b; 126: 1398–1403
   PubMed Web of Science ®Google Scholar
• Vergier B., de Muret A., Beylot-Barry M., Vaillant L., Ekouevi D., Chene G., Carlotti A., Franck N., Dechelotte P., Souteyrand P., Courville P., Joly P., Delaunay M., Bagot M., Grange F., Fraitag S., Bosq J., Petrella T., Durlach A., De Mascarel A., Merlio J. P., Wechsler J. Transformation of mycosis fungoides: Clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000; 95: 2212–2218
   PubMed Web of Science ®Google Scholar
• Wahl A. F., Klussman K., Thompson J. D., Chen J. H., Francisco L. V., Risdon G., Chace D. F., Siegall C. B., Francisco J. A. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects anti-tumor activity in models of Hodgkin's disease. Cancer Res. 2002; 62: 3736–3742
   PubMed Web of Science ®Google Scholar
• Waldmann T. A. The structure, function, and expression of interleukin-2 receptors on normal and malignant T-cells. Science 1986; 232: 727–732
   PubMed Web of Science ®Google Scholar
• Waldmann T. A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006; 6: 595–601
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., White J. D., Carrasquillo J. A., Reynolds J. C., Paik C. H., Gansow O. A., Brechbiel M. W., Jaffe E. S., Fleisher T. A., Goldman C. K., Top L. E., Bamford R., Zaknoen E., Roessler E., Kasten-Sportes C., England R., Litou H., Johnson J. A., Jackson-White T., Manns A., Hanchard B., Junghans R. P., Nelson D. L. Radioimmunotherapy of interleukin-2Rα -expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995; 86: 4063–4075, 1995
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., White J. D., Goldman C. K., Top L., Grant A., Bamford R., Roessler E., Horak I. D., Zaknoen S., Kasten-Sportes C., England R., Horak E., Mishra B., Dipre M., Hale P., Fleisher T. A., Junghans R. P., Jaffe E. S., Nelson D. L. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993; 82: 1701–1712
   PubMed Web of Science ®Google Scholar
• Wong B. Y., Gregory S. A., Dang N. H. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest. 2007; 25: 495–501
   PubMed Web of Science ®Google Scholar
• Zamai L., Del Zotto G., Papa S. CD122 (interleukin-2 receptor beta subunit). J. Biol. Regul. Homeost. Agents 2001; 15: 95–97, 2001
   PubMedGoogle Scholar
• Zhang M., Zhang Z., Garmestani K., Goldman C. K., Ravetch J. V., Brechbiel M. W., Carrasquillo J. A., Waldmann T. A. Activating Fc receptors are required for anti-tumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res. 2004; 64: 5825–5829
   PubMed Web of Science ®Google Scholar
• Zhang Z., Zhang M., Goldman C. K., Ravetch J. V., Waldmann T. A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003a; 63: 6453–6457
   PubMed Web of Science ®Google Scholar
• Zhang Z., Zhang M., Ravetch J. V., Goldman C., Waldmann T. A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 2003b; 102: 284–288
   PubMedGoogle Scholar